Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. 1994

L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
Medical College of Ohio, Department of Biochemistry and Molecular Biology, Toledo 43614.

The role of transforming growth factor (TGF) beta type II receptor in reversing the malignant phenotype of human breast cancer MCF-7 cells was examined. MCF-7 cells were insensitive to TGF beta 1 and expressed undetectable levels of cell surface TGF beta type I receptor (RI) and type II receptor (RII) by cross-linking with 125I-TGF beta 1. Stable transfection of a RII expression vector yielded 3 transfectants with varying levels of exogenous RII mRNA and protein levels. Expression of RII also increased TGF beta 1 binding to RI in all 3 clones. Proliferation of RII-positive clones was inhibited by exogenous TGF beta 1 in a dose-dependent manner, whereas the control clones remained TGF beta-insensitive. The RII transfectants were growth arrested in monolayer culture at saturation densities which were 41-66% of that of the Neo controls. They also showed reduced clonogenicity in soft-agarose. Tumorigenicity in ovariectomized, estrogen-supplemented nude mice was delayed in transfectants with low RII levels. Transfectants expressing high levels of RII showed a large reduction in tumorigenicity as well as a longer delay in tumor formation. Tumor growth was associated with loss of exogenous RII expression in transfectants. The results indicate that when systems for TGF beta signal transduction are intact, reconstitution of the TGF beta receptor system can lead to reversion of malignancy in cells lacking RII.

UI MeSH Term Description Entries
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
August 1998, Journal of cellular physiology,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
March 1998, The Journal of biological chemistry,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
May 1997, The Journal of biological chemistry,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
April 2000, The Journal of biological chemistry,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
July 1996, The Journal of biological chemistry,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
January 1998, International journal of oncology,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
July 1997, Cancer research,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
June 1998, Journal of cellular physiology,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
March 2010, Acta pharmacologica Sinica,
L Sun, and G Wu, and J K Willson, and E Zborowska, and J Yang, and I Rajkarunanayake, and J Wang, and L E Gentry, and X F Wang, and M G Brattain
November 2002, Cancer research,
Copied contents to your clipboard!